INNOVATION IN PHOTODYNAMIC THERAPY



DUSA PHARMACEUTICALS, INC.

FOR RELEASE AT 8:00 A.M.



                   DUSA PHARMACEUTICALS REPORTS SECOND QUARTER

                   CORPORATE HIGHLIGHTS AND FINANCIAL RESULTS



WILMINGTON, MA. AUGUST 13, 2002 - DUSA Pharmaceuticals, Inc. (NASDAQ NMS: DUSA)

reported today its corporate highlights and financial results for the second

quarter ended June 30, 2002.



CORPORATE HIGHLIGHTS

As previously reported, on June 6, 2002, DUSA received a notice of termination

from Schering AG, its worldwide (except Canada) Levulan(R) PDT dermatology

marketing partner of the parties' Marketing Development and Supply Agreement

dated November 22, 1999. As a result, within the one-year notice period, DUSA

will reacquire from Schering AG all rights that had been granted under the

agreement. However, the parties are currently negotiating plans to arrange for a

smooth and efficient transfer of responsibilities with an accelerated

termination date.



During the second quarter, Berlex Laboratories, Schering AG's United States

affiliate reported that end-user Levulan(R) Kerastick(R) sales totaled 2,250

units, up from 1,848 in Q1, but below the 2,448 units sold to end-users in Q4

2001. The installed base of BLU-U(R) brand light units increased modestly to 369

at June 30, 2002 as compared to 328 at March 31, 2002.



Despite the disappointing sales to this point, DUSA continues to receive reports

from doctors, who are using Levulan(R) PDT for their patients, who are very

pleased with the product and its results. There have also been a number of

recent articles in the dermatology press highlighting the benefits of Levulan(R)

PDT for the treatment of actinic keratoses (AKs).



DUSA is currently preparing its own development, marketing and publication plans

that it intends to implement following the actual termination date of the

Schering AG relationship. Although these plans are still being formulated, DUSA

has decided not to create a nationwide sales force, or to seek a new dermatology

marketing partner at this time. Therefore, the Company does not expect any

significant near-term changes in Kerastick(R) sales levels, and/or BLU-U(R)

placements. However, the Company will continue to work towards a more widespread

adoption of our technology as doctors become more familiar with the benefits of

Levulan(R) PDT, and as the Company seeks to achieve improved reimbursement

levels.



The Company intends to focus its near-term dermatology development program on

the Broad Area Actinic Keratoses (BAAK) indication, with the goal of achieving a

label-change for the current products, as well as finishing its FDA-required

Phase IV long-term AK Tracking Study. As reported previously, the preliminary

results of DUSA's Phase I/II study on resistant plantar warts were encouraging,

Home        Intelligence        Services        Subscriptions        News        About Us

Contact Us       Terms of Use       Resend Documents       Shopping Cart

Copyright © 2008 The Consus Group LLC